We believe every breakthrough treatment deserves a fair chance to reach the right patients. That’s why we partner with pharma, biotech, and medtech leaders to prove value, accelerate access, and improve patient outcomes faster than anyone else.
Alkemi was built to solve a problem we witnessed too many times: great therapies failing to reach patients because of preventable access mistakes.
We saw treatments stumble because the wrong evidence was built. Because the wrong decision makers were prioritized. Because teams reacted too slowly to market change.
We knew there had to be a better way.
So we set out to create a consulting partner that breaks silos, moves faster, and delivers solutions that anticipate change instead of chasing it.
Today, that vision drives everything we do: helping life science companies navigate complex market dynamics and bring better options to patients.
.avif)
Behind every therapy is a person hoping for relief, a family searching for answers, and a health system balancing cost-effectiveness with access.
When access breaks down, patients pay the price. We exist to prevent that.
That means helping lifesciences companies:
Gain insights that drive meaningful decisions
Build evidence that resonates with access decision-makers (patients/care givers, payers, HCPs, guidelines, HTA agencies, health systems, etc.)
Align stakeholders so no cycles are wasted
Deliver HEOR and market access strategies that broaden your impact, fast.
We adapt to the realities our clients face: budget pressures, time constraints, organizational silos, and data gaps.
Our team brings decades of combined experience in evidence planning, market access, health economics, outcomes research, and commercialization services.
From U.S. payers to European HTAs, we provide local insight with international impact, including language and cultural expertise.
.avif)
We don’t stop at analysis. We move quickly from research to launch strategy with innovative solutions that support real-world decision making with actions you can take now.
“Access strategies executed in 90 days instead of 6-12 months, enabling us to act within the critical 30-day decision window, when access positions were still in flux and competitors were unprepared.”
“I wanted to reach out and tell you that the publication is getting GREAT reception from senior BU leadership across the company. Thank you again for your and Alkemi’s support on this project!”
“Stakeholder-validated access arguments built in 42 days, helping us retain Tier 2 formulary status and neutralize a competitor’s evidence positioning before revenue was impacted.”
“Payer value models and communication tools delivered in 45 days, giving our team immediate readiness for coverage discussions, cutting months from pricing and reimbursement timelines.”
"Really appreciate your support - as you know I rang you in a bit of a panic a few weeks ago, yet the session came across as though you’d been working on it for months. Thank you so much - this is an important event for our team, companies and clients - and you really helped make it a success. I heard 3 groups leave with ambitions to up their game - and they’re the 3 that need to do it the most - so the message landed as well."
“Patient access achieved 6 days post-approval, driving a 140% revenue increase and 90% share-price growth within 12 months through a precision-aligned market access plan.”
“Coverage positions worth $100M+ preserved after policy risks were contained and access arguments re-framed within 45 days of the initial threat.”
"When I presented the project output to our leadership, they said: 'You took a really scary situation and broke it down in terms we understand. It sounds like the team has a clear plan going forward'.
“Launch readiness across 7 key markets accelerated by 6 months, improving payer perception, price confidence, and HTA alignment for sustained commercial success.”
“Cross-functional alignment reached in 21 days, uniting medical, HEOR, and commercial stakeholders around payer-critical priorities and evidence generation plans.”
“Research engagement delivered 5X more patients and 6X more clinicians than prior studies, compressing evidence-collection timelines by over 12 months.”
"Thanks to the whole team involved in staging this Advisory Council. I was fortunate to be able to attend and here the insights from the council members firsthand. The report provides an excellent summary."
“Guideline and compendia updates secured within 7 days of approval, converting scientific validation into immediate payer endorsement and market adoption.”
The healthcare landscape isn’t slowing down. Neither are we. If you’re preparing for a product launch, navigating drug pricing, or strengthening your health technology assessment strategy, Alkemi helps you align, act, and deliver with confidence.